Fruition Biologics

Fruition Biologics is a biotechnology company focused on developing next-generation genetic medicines using an advanced AAV engineering platform. Founded by pioneers in the field of directed evolution, the company aims to overcome the limitations of current viral vectors by creating novel AAV capsids with improved tissue specificity, reduced immunogenicity, and enhanced delivery efficiency. Fruition Biologics is backed by prominent life science investors, including The Column Group, and is leveraging its proprietary technology to build a pipeline of gene therapies for high-need therapeutic areas. The company operates primarily in a pre-clinical stage, focusing on optimizing delivery for complex genetic disorders. By utilizing high-throughput screening and machine learning, Fruition Biologics seeks to expand the therapeutic window of gene therapy across multiple organ systems.